Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 22.1% in February

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 16,000 shares, an increase of 22.1% from the January 31st total of 13,100 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average trading volume of 48,600 shares, the days-to-cover ratio is presently 0.3 days.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC bought a new stake in Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene at the end of the most recent reporting period. 10.40% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Evogene in a report on Sunday, March 2nd. They issued a “sell” rating on the stock.

Evogene Trading Down 0.2 %

EVGN stock opened at $1.41 on Friday. Evogene has a twelve month low of $1.20 and a twelve month high of $9.90. The company’s 50 day moving average is $1.58 and its two-hundred day moving average is $2.08. The stock has a market cap of $7.57 million, a P/E ratio of -0.32 and a beta of 1.29.

Evogene (NASDAQ:EVGN) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. The company had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same quarter last year, the company earned ($1.30) earnings per share.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.